首页 | 本学科首页   官方微博 | 高级检索  
检索        


EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus,contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
Authors:Yuki Uchihara  Kenji Tago  Hiroomi Tamura  Megumi Funakoshi&#x;Tago
Institution:1. Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo Japan ; 2. Division of Structural Biochemistry, Department of Biochemistry, Jichi Medical University, Shimotsuke‐shi Japan
Abstract:The oncogenic fusion protein nucleophosmin‐anaplastic lymphoma kinase (NPM‐ALK), found in anaplastic large‐cell lymphoma (ALCL), localizes to the cytosol, nucleoplasm, and nucleolus. However, the relationship between its localization and transforming activity remains unclear. We herein demonstrated that NPM‐ALK localized to the nucleolus by binding to nucleophosmin 1 (NPM1), a nucleolar protein that exhibits shuttling activity between the nucleolus and cytoplasm, in a manner that was dependent on its kinase activity. In the nucleolus, NPM‐ALK interacted with Epstein–Barr virus nuclear antigen 1‐binding protein 2 (EBP2), which is involved in rRNA biosynthesis. Moreover, enforced expression of NPM‐ALK induced tyrosine phosphorylation of EBP2. Knockdown of EBP2 promoted the activation of the tumor suppressor p53, leading to G0/G1‐phase cell cycle arrest in Ba/F3 cells transformed by NPM‐ALK and ALCL patient‐derived Ki‐JK cells, but not ALCL patient‐derived SUDH‐L1 cells harboring p53 gene mutation. In Ba/F3 cells transformed by NPM‐ALK and Ki‐JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC‐0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1. These results suggest that the knockdown of EBP2 triggered p53 activation through the Akt‐mTORC1 pathway in NPM‐ALK‐positive cells. Collectively, the present results revealed the critical repressive mechanism of p53 activity by EBP2 and provide a novel therapeutic strategy for the treatment of ALCL.

Abbreviations

ALCL
anaplastic large‐cell lymphoma
EBP2
EBNA1‐binding protein 2
IMT
inflammatory myofibroblastic tumors
mTOR
mechanistic target of rapamycin
mTORC1
mTOR complex 1
NoLS
nucleolar localization signal
NPM1
nucleophosmin 1
NPM‐ALK
nucleophosmin‐anaplastic lymphoma kinase
NSCLC
non‐small cell lung cancer
TPM3
tropomyosin 3
Keywords:Akt  EBP2  mTORC1  NPM‐  ALK  nucleolus  p53
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号